02:11 PM EST, 11/13/2025 (MT Newswires) -- Nexalin Technology ( NXL ) said Thursday it entered into a distribution agreement with Israeli medical device distributor Carmi Masha Technologies to market and sell its Gen-2 Console non-invasive neurostimulation device throughout Israel.

The agreement follows regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of the device for the treatment of mental health disorders, including insomnia, depression, and anxiety.

Under the terms of the agreement, Carmi Masha will manage sales, marketing, clinical education, importation, registration, and distribution of the Gen-2 device across hospitals, clinics, and private treatment centers.

The company also said it plans to explore potential future applications of the technology in post-traumatic stress disorder, traumatic brain injury, Alzheimer's disease, and other forms of dementia, together with Carmi Masha.

Shares of Nexalin Technology ( NXL ) were down 5.5% in recent trading.

Price: 1.19, Change: -0.07, Percent Change: -5.56